Clinical trials
Biliary Tract Neoplasms trials in Taiwan
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
37 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2010 | 1 |
| 2013 | 1 |
| 2014 | 1 |
| 2015 | 1 |
| 2016 | 2 |
| 2017 | 2 |
| 2018 | 3 |
| 2019 | 5 |
| 2020 | 1 |
| 2021 | 2 |
| 2022 | 6 |
| 2023 | 4 |
| 2024 | 4 |
| 2025 | 2 |
| 2026 | 2 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 13 |
| Recruiting | 11 |
| Active, not recruiting | 7 |
| Terminated | 4 |
| Not yet recruiting | 2 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| AstraZeneca | 8 |
| National Health Research Institutes, Taiwan | 5 |
| InnoPharmax Inc. | 3 |
| ASLAN Pharmaceuticals | 2 |
| EMD Serono Research & Development Institute, Inc. | 2 |
| Hoffmann-La Roche | 2 |
| Merck Sharp & Dohme LLC | 2 |
| AbGenomics B.V Taiwan Branch | 1 |
| AbbVie | 1 |
| Amgen | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Biliary Tract Neoplasms | 37 |
| Cholangiocarcinoma | 11 |
| Colorectal Neoplasms | 6 |
| Gallbladder Neoplasms | 6 |
| Stomach Neoplasms | 6 |
| Neoplasms | 5 |
| Bile Duct Neoplasms | 4 |
| Carcinoma, Hepatocellular | 4 |
| Pancreatic Neoplasms | 4 |
| Squamous Cell Carcinoma of Head and Neck | 4 |
Trials
Showing 51 to 37 of 37. Each trial links to its page on Pharma Observatory.
No trials match these filters.
Try a different keyword, or clear a filter.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.